Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Operating Leases: 2019-2025

Historic Operating Leases for RedHill Biopharma (RDHL) over the last 5 years, with Jun 2025 value amounting to $214,000.

  • RedHill Biopharma's Operating Leases fell 41.85% to $214,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $214,000, marking a year-over-year decrease of 41.85%. This contributed to the annual value of $3,000 for FY2024, which is 99.34% down from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Operating Leases is $214,000, which was up 7,033.33% from $3,000 recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Operating Leases ranged from a high of $7.2 million in Q1 2022 and a low of $3,000 during Q4 2024.
  • For the 3-year period, RedHill Biopharma's Operating Leases averaged around $1.4 million, with its median value being $411,500 (2023).
  • As far as peak fluctuations go, RedHill Biopharma's Operating Leases surged by 150.31% in 2022, and later tumbled by 99.34% in 2024.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Operating Leases stood at $2.6 million in 2021, then soared by 150.31% to $6.4 million in 2022, then slumped by 92.94% to $455,000 in 2023, then plummeted by 99.34% to $3,000 in 2024, then crashed by 41.85% to $214,000 in 2025.
  • Its Operating Leases was $214,000 in Q2 2025, compared to $3,000 in Q4 2024 and $368,000 in Q2 2024.